Evidence map›Paper›PMID 25870988›Full record

ArticleAIDS (London, England)2015

Young age at start of antiretroviral therapy and negative HIV antibody results in HIV-infected children when suppressed.

Louise Kuhn, Diana B Schramm, Stephanie Shiau, Renate Strehlau, Francoise Pinillos, Karl Technau, Ashraf Coovadia, Elaine J Abrams, Adrian Puren, Caroline T Tiemessen

Open access · greenAbstract read
In one paragraph

Article in AIDS (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Quantitative Human Immunodeficiency Virus (HIV)-1 Antibodies Correlate With Plasma HIV-1 RNA and Cell-associated DNA Levels in Children on Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. The Contributions of Clinical Pharmacology to HIV Cure Research.Clinical pharmacology and therapeutics · 2021
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Louise KuhnaGertrude H. Sergievsky Center, College of Physicians and Surgeons bDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA cCentre for HIV and STIs, National Institute for Communicable Diseases dEmpilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa eICAP, Mailman School of Public Health, Columbia University, New York, New York, USA.
Diana B Schramm
Stephanie Shiau
Renate Strehlau
Francoise Pinillos
Karl Technau
Ashraf Coovadia
Elaine J Abrams
Adrian Puren
Caroline T Tiemessen
University of the Witwatersrand · ZANational Institute for Communicable DiseasesColumbia University · USRoyal College of Physicians · GB

Funding

Host epigenetic and mitochondrial function in HIV-infected childrenR01HD073952 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KUHN, LOUISE · 2012 to 2016
$3.7M
Treatment Options for Protease Inhibitor Exposed ChildrenR01HD061255 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KUHN, LOUISE · 2010 to 2014
$2.9M
Clinical Relevance of Transient Nevirapine ResistanceR01HD047177 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KUHN, LOUISE · 2004 to 2008
$2.6M
NICHD NIH HHS HD047177NICHD NIH HHS HD061255NICHD NIH HHS R01 HD047177NICHD NIH HHS R01 HD061255NICHD NIH HHS R01 HD073952
6 · The paper itself

Abstract

backgroundNegative results on standard HIV antibody tests have been described among HIV-infected children suppressed on antiretroviral therapy (ART) started early in life. Here, we describe the frequency and predictors of this phenomenon in a well characterized cohort of treated children.

methodsWe selected samples from 103 HIV-infected children who started ART 14 months of age or less and from 122 children who started 6 months of age or less followed as part of two sequential clinical trials in Johannesburg, South Africa. Children had attained viral suppression on ART and had received ART for between 3 and 6.4 years (mean 4.3 years) when tested for HIV antibody using a standard ELISA (Genescreen HIV1/2 version 2; Bio-rad).

resultsOnly children 6 months of age or less when ART was started had negative antibody results when tested after suppression on ART several years later. Negative or low-positive antibody results were observed in 40.0, 37.0 and 27.8% of children starting ART less than 2 months of age, or starting during month 2 or 3, respectively. This dropped to 5.9, 3.5 and 5.3% if ART was started during month 4, 5 and 6, respectively. Higher CD4 percentage prior to ART initiation and no recorded intermittent viremia also predicted negative antibody results.

conclusionTesting negative on standard HIV antibody tests occurs fairly commonly among HIV-infected children who started ART 3 months of age or less and are virally suppressed. It would be prudent in clinical practice to avoid HIV antibody tests among virally suppressed, early-treated children to prevent unnecessary confusion.

Indexed as

Age FactorsAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveChildChild, PreschoolEnzyme-Linked Immunosorbent AssayFemaleHIV AntibodiesHIV InfectionsHumansInfantMaleSouth AfricaAnti-Retroviral AgentsHIV Antibodies

Identifiers

PMID25870988
PMCPMC4538987
OpenAlexW2044228371

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.